Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids

Patent metadata

Field	Value
Publication number	US-10808228-B2
Application number	US-201815865713-A
Country	US
Kind code	B2
Filing date	Jan 9, 2018
Priority date	Jan 26, 2012
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

First claim

The invention claimed is:

1. A human immunodeficiency virus comprising an alkyne-modified fatty acid moiety, wherein the moiety is non-naturally occurring, and
wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl or 12-ethynyldodecanyl.

2. The virus of claim 1 , wherein the virus is HIV-1.

3. The virus of claim 1 , wherein the virus is inactivated.

4. The virus of claim 1 , wherein the virus is attenuated.

5. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl.

6. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is attached to the virus by an amide or a thioester bond.

7. A composition comprising the virus of claim 1 .

8. The composition of claim 7 , further comprising a pharmaceutically acceptable excipient.

9. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is 12-ethynyldodecanyl.

10. An in vitro method of producing the human immunodeficiency virus of claim 1 , the method comprising contacting the virus with the alkyne-modified fatty acid moiety in an amount effective to enhance the infectivity of the virus.

11. The method of claim 10 , wherein the virus is in a cell.

12. The method of claim 11 , wherein the cell is a human animal cell or a non-human animal cell.

13. The method of claim 10 , wherein the human immunodeficiency virus is HIV-1.

14. The method of claim 10 , wherein the contacting is performed in a solution comprising at least one of animal serum, amino acids, buffers, fatty acids, glucose, hormones, inorganic salts, lipids, metal ion chelators, peptides, surfactants, trace metals, and vitamins.

Assignees

• Life Technologies Corp
• Univ Johns Hopkins

Inventors

• Agnew Brian
• Graham David

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2740/16045

  Special targeting system for viral vectors · CPC title

• C12N2810/10

  Vectors comprising a non-peptidic targeting moiety · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title